Last reviewed · How we verify

Low-dose PRP

Hospital for Special Surgery, New York · FDA-approved active Biologic

Low-dose PRP (platelet-rich plasma) delivers concentrated platelets and growth factors to damaged tissues to promote healing and reduce inflammation.

Low-dose PRP (platelet-rich plasma) delivers concentrated platelets and growth factors to damaged tissues to promote healing and reduce inflammation. Used for Osteoarthritis (knee, hip, shoulder), Tendinopathy and ligament injuries, Muscle injuries.

At a glance

Generic nameLow-dose PRP
SponsorHospital for Special Surgery, New York
Drug classAutologous cell therapy / Regenerative medicine product
ModalityBiologic
Therapeutic areaOrthopedics / Regenerative Medicine
PhaseFDA-approved

Mechanism of action

PRP is an autologous blood product prepared by centrifuging a patient's own blood to concentrate platelets, which contain growth factors (PDGF, VEGF, FGF, TGF-β) and cytokines. When injected into injured or degenerative tissues, these factors stimulate angiogenesis, cell proliferation, and tissue remodeling. The low-dose formulation aims to optimize therapeutic benefit while minimizing volume and cost.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: